Read by QxMD icon Read

CoreValve evolut

A B Gopalamurugan, K Murali, B Jyotsana, A Jacob, V V Bashi
Transcatheter Aortic Valve Implantation (TAVI) is a well-described treatment for symptomatic calcific severe aortic stenosis. However, TAVI technology is being increasingly used around the world to treat selected cases of severe aortic regurgitation (AR). One of the main limitations of using TAVI technology for AR is the lack of calcification, which is common in such cases. This makes anchoring of a TAVI prosthesis to the aortic annulus difficult and risks displacement or embolization. However, with the availability of recapturable and repositionable TAVI technologies, these limitations have been overcome to a large extent...
September 2016: Indian Heart Journal
Matheus Simonato, Ali N Azadani, John Webb, Jonathon Leipsic, Ran Kornowski, Alec Vahanian, David Wood, Nicolo Piazza, Susheel Kodali, Jian Ye, Brian Whisenant, Diego Gaia, Mina Aziz, Tilak Pasala, Julinda Mehilli, Harindra C Wijeysundera, Didier Tchetche, Neil Moat, Rui Teles, Anna Sonia Petronio, David Hildick-Smith, Uri Landes, Stephan Windecker, Yaron Arbel, Oscar Mendiz, Raj Makkar, Elaine Tseng, Danny Dvir
AIMS: Transcatheter heart valve (THV) implantation in failed bioprosthetic valves (valve-in-valve [ViV]) offers an alternative therapy for high-risk patients. Elevated post-procedural gradients are a significant limitation of aortic ViV. Our objective was to assess the relationship between depth of implantation and haemodynamics. METHODS AND RESULTS: Commercially available THVs used for ViV were included in the analysis (CoreValve Evolut, SAPIEN XT and the Portico valve)...
September 18, 2016: EuroIntervention
Mike Saji, D Scott Lim
Following the first successful transcatheter aortic valve replacement (TAVR) in 2002, TAVR has globally evolved to become a standard procedure in high-risk patients. Surgical aortic valve replacement in non-high-risk patients remains the gold standard for treatment of severe aortic stenosis. However, a paradigm shift appears to be occurring in the direction of treating lower-risk patients, and several studies have suggested its impact on clinical outcomes. In this review, we highlight the current status of TAVR in intermediate-risk patients and review major trials including Placement of AoRTic TraNscathetER (PARTNER) 2A randomized intermediate-risk trial using SAPIEN XT (Edwards Lifesciences Corp, Irvine, CA) recently presented with excellent outcomes and the lowest major complications rate at the American College of Cardiology's 65th Annual Scientific Session in Chicago...
October 2016: Current Cardiology Reports
Marco Barbanti, John G Webb, Claudia Tamburino, Nicolas M Van Mieghem, Raj R Makkar, Nicolò Piazza, Azeem Latib, Jan-Malte Sinning, Kim Won-Keun, Sabine Bleiziffer, Francesco Bedogni, Samir Kapadia, Didier Tchetche, Josep Rodés-Cabau, Claudia Fiorina, Luis Nombela-Franco, Federico De Marco, Peter P de Jaegere, Tarun Chakravarty, Beatriz Vaquerizo, Antonio Colombo, Lars Svensson, Rüdiger Lange, Georg Nickenig, Helge Möllmann, Thomas Walther, Francesco Della Rosa, Yacine Elhmidi, Danny Dvir, Nedy Brambilla, Sebastiano Immè, Carmelo Sgroi, Simona Gulino, Denise Todaro, Gerlando Pilato, Anna Sonia Petronio, Corrado Tamburino
BACKGROUND: Transcatheter aortic valves can degenerate in a manner similar to surgical bioprostheses. METHODS AND RESULTS: Clinical and echocardiographic outcomes of patients who underwent redo transcatheter aortic valve replacement (TAVR) procedures >2 weeks post procedure were collected from 14 centers. Among 13 876 patients, 50 (0.4%) underwent redo TAVR procedure at participating centers. Indications for redo TAVR were moderate-severe prosthetic aortic valve stenosis (n=10, 21...
September 2016: Circulation. Cardiovascular Interventions
Hesham K Abdelaziz, Andrew Wiper, Tarek Al-Badawi, Augustine Tang, Ranjit More, David H Roberts
We describe a case of balloon assisted retraction of a migrated CoreValve Evolut R bioprosthesis during trans-femoral TAVI.
July 20, 2016: Cardiovascular Revascularization Medicine: Including Molecular Interventions
Omar Issa, Kanna Posina, Ivan Arenas, Esteban Escolar, Angelo La Pietra, Nirat Beohar
No abstract text is available yet for this article.
July 25, 2016: JACC. Cardiovascular Interventions
James Cockburn, Maureen Dooley, Jessica Parker, Andrew Hill, Nevil Hutchinson, Adam de Belder, Uday Trivedi, David Hildick-Smith
BACKGROUND: Redo surgery for degenerative bioprosthetic aortic valves is associated with significant morbidity and mortality. Report results of valve-in-valve therapy (ViV-TAVI) in failed supra-annular stentless Freedom Solo (FS) bioprostheses, which are the highest risk for coronary occlusion. METHODS: Six patients with FS valves (mean age 78.5 years, 50% males). Five had valvular restenosis (peak gradient 87.2 mm Hg, valve area 0.63 cm(2) ), one had severe regurgitation (AR)...
June 17, 2016: Catheterization and Cardiovascular Interventions
Matheus Simonato, John Webb, Ran Kornowski, Alec Vahanian, Christian Frerker, Henrik Nissen, Sabine Bleiziffer, Alison Duncan, Josep Rodés-Cabau, Guilherme F Attizzani, Eric Horlick, Azeem Latib, Raffi Bekeredjian, Marco Barbanti, Thierry Lefevre, Alfredo Cerillo, José María Hernández, Giuseppe Bruschi, Konstantinos Spargias, Alessandro Iadanza, Stephen Brecker, José Honório Palma, Ariel Finkelstein, Mohamed Abdel-Wahab, Pedro Lemos, Anna Sonia Petronio, Didier Champagnac, Jan-Malte Sinning, Stefano Salizzoni, Massimo Napodano, Claudia Fiorina, Antonio Marzocchi, Martin Leon, Danny Dvir
BACKGROUND: Transcatheter valve implantation inside failed bioprosthetic surgical valves (valve-in-valve [ViV]) may offer an advantage over reoperation. Supra-annular transcatheter valve position may be advantageous in achieving better hemodynamics after ViV. Our objective was to define targets for implantation that would improve hemodynamics after ViV. METHODS AND RESULTS: Cases from the Valve-in-Valve International Data (VIVID) registry were analyzed using centralized core laboratory assessment blinded to clinical events...
June 2016: Circulation. Cardiovascular Interventions
Matteo Pagnesi, Richard J Jabbour, Azeem Latib, Hiroyoshi Kawamoto, Akihito Tanaka, Damiano Regazzoli, Antonio Mangieri, Claudio Montalto, Marco B Ancona, Francesco Giannini, Alaide Chieffo, Matteo Montorfano, Fabrizio Monaco, Alessandro Castiglioni, Ottavio Alfieri, Antonio Colombo
Balloon predilation is historically considered a requirement before performing transcatheter aortic valve implantation (TAVI). As the procedure has evolved, it has been questioned whether it is actually needed, but data are lacking on mid-term outcomes. The aim of this study was to evaluate the effect of balloon predilation before TAVI. A total of 517 patients who underwent transfemoral TAVI from November 2007 to October 2015 were analyzed. The devices implanted included the Medtronic CoreValve (n = 216), Medtronic Evolut R (n = 30), Edwards SAPIEN XT (n = 210), and Edwards SAPIEN 3 (n = 61)...
July 1, 2016: American Journal of Cardiology
Neil Ruparelia, Azeem Latib, Hiroyoshi Kawamoto, Nicola Buzzatti, Francesco Giannini, Filippo Figini, Antonio Mangieri, Damiano Regazzoli, Stefano Stella, Alessandro Sticchi, Akihito Tanaka, Marco Ancona, Eustachio Agricola, Fabrizio Monaco, Pietro Spagnolo, Alaide Chieffo, Matteo Montorfano, Ottavio Alfieri, Antonio Colombo
BACKGROUND: Transcatheter aortic valve implantation (TAVI) is the treatment of choice for high-risk patients presenting with severe symptomatic aortic stenosis. The aim of this study was to investigate the impact of second-generation (2G) devices in comparison to first-generation (1G) devices with regard to procedural and short-term clinical outcomes. METHODS: Between November 2007 and May 2015, a total of 449 patients treated with 1G TAVI devices (Edwards Sapien XT, Medtronic CoreValve) were propensity matched (1:1) to 179 patients treated with 2G TAVI devices (Edwards Sapien 3, Medtronic Evolut R, Boston Scientific Lotus, Direct Flow Medical)...
May 2016: Journal of Invasive Cardiology
Daniela Serio, Mirko Doss, Won-Keun Kim, Helge Möllmann, Thomas Walther
Transcatheter aortic valve implantation (TAVI) has been established as a therapeutic option in patients with a high procedural risk presenting with severe aortic stenosis. Recent improvements of TAVI technology made it possible to treat degenerated bioprosthesis using the valve-in-valve implantation concept. The self-expanding CoreValve (Medtronic, Minneapolis, MN) prosthesis has recently been redesigned and was introduced into clinical practice. We report a case of a not fully expanded Medtronic CoreValve Evolut R after deploying a 26 mm prosthesis into a degenerated 25 mm Carpentier-Edwards Perimount prosthesis...
May 2016: Annals of Thoracic Surgery
Gabriel Maluenda, Carlos Caorsi, Cristian Baeza
Transcatheter aortic valve replacement remains challenge in patients with ball-cage-type mechanical valve in mitral position. Potential under-expansion of the percutaneous valve and interaction between the mitral ball-cage mechanical valve tilted towards the left ventricular outflow tract and the percutaneous valve adds risk during and after implantation. We report a successful implantation of the novel CoreValve Evolut-R self-expanding in a patient with severe aortic stenosis and a mitral Starr-Edwards mechanical valve implanted 28years ago...
June 2016: Cardiovascular Revascularization Medicine: Including Molecular Interventions
Manolis Vavuranakis, Konstantinos Kalogeras, Dimitrios Tousoulis
The application of transcatheter aortic valve implantation (TAVI) in a wider and younger population in the near future makes the need to successfully deal with challenging procedural conditions an imperative. We report a case in which TAVI was successfully conducted in a patient with aortic coarctation using a last-generation low-profile bioprosthesis. Despite the fragile aortic wall and its possible abnormal function, a low-profile (14F) CoreValve Evolute R device (Medtronic, Minneapolis, MN) was implanted through the coarctation without complications...
January 25, 2016: Canadian Journal of Cardiology
Ana Isabel Azevedo, Ricardo Ladeiras-Lopes, Alberto Rodrigues, Pedro Braga, Vasco Gama Ribeiro
No abstract text is available yet for this article.
January 2016: Arquivos Brasileiros de Cardiologia
Maurizio Taramasso, Fabian Nietlispach, Markus Schmid, Francesco Maisano
No abstract text is available yet for this article.
January 14, 2016: European Heart Journal
Giuseppe Bruschi, Francesco Soriano, Francesco Musca, Stefano Nava, Arturo Einaudi, Andrea Garascia, Oriana Belli, Alberto Barosi, Pasquale Fratto, Paola Colombo, Claudio Francesco Russo, Maria Pia Gagliardone, Silvio Klugmann
No abstract text is available yet for this article.
September 2015: EuroIntervention
Ganesh Manoharan, Antony S Walton, Stephen J Brecker, Sanjeevan Pasupati, Daniel J Blackman, Hongyan Qiao, Ian T Meredith
OBJECTIVES: The purpose of this study was to prospectively evaluate the safety and clinical performance of the CoreValve Evolut R transcatheter aortic valve replacement (TAVR) system (Medtronic, Inc., Minneapolis, Minnesota) in a single-arm, multicenter pivotal study in high- or extreme-risk patients with symptomatic aortic valve stenosis. BACKGROUND: Although outcomes following TAVR are improving, challenges still exist. The repositionable 14-F equivalent CoreValve Evolut R TAVR system was developed to mitigate some of these challenges...
August 24, 2015: JACC. Cardiovascular Interventions
Manolis Vavuranakis, Dimitrios A Vrachatis, Gerasimos Siasos, Sophia Vaina, Konstantinos Filis, Fragiska Sigala, Konstantinos Kalogeras, Angelos-Michail Kolokathis, Carmen Moldovan, Theodore G Papaioannou, Constantina Aggeli, Dimitrios Tousoulis
We report the first TAVI procedure in Greece to use the CoreValve Evolut-R (23 mm profile) bioprosthesis with the InLine sheath and the EnVeo loading guiding catheter in a patient with small anatomical characteristics (aortic annulus, access vessel) and severe comorbidities. The procedure was successfully conducted under general anesthesia through a surgically prepared, extensively calcified, left femoral artery.
July 2015: Hellenic Journal of Cardiology: HJC, Hellēnikē Kardiologikē Epitheōrēsē
Vincent Auffret, Marc Bedossa, Dominique Boulmier, Jean Philippe Verhoye, Vito Giovanni Ruggieri, René Koning, Marc Laskar, Éric Van Belle, Pascal Leprince, Jean Philippe Collet, Bernard Iung, Thierry Lefèvre, Helene Eltchaninoff, Martine Gilard, Hervé Le Breton
Transcatheter aortic valve implantation (TAVI) is indicated in patients with severe symptomatic aortic stenosis who are not suitable for surgery or should be considered when there is a high surgical risk as assessed by a heart team. There is a decrease in mean logistic EuroSCORE since January 2010, which translates a gradual evolution in patients' selection. Expertise of geriatricians to further assess frailty is a key step in the risk stratification process of this elderly population (mean age: 83.4±7.3 years)...
July 2015: La Presse Médicale
Giuseppe Bruschi, Federico De Marco, Luca Botta, Alberto Barosi, Paola Colombo, Silvia Mauri, Aldo Cannata, Nuccia Morici, Tiziano Colombo, Pasquale Fratto, Sandra Nonini, Francesco Soriano, Michele Mondino, Cristina Giannattasio, Silvio Klugmann
OBJECTIVE: Transcatheter aortic valve implantation (TAVI) has been designed to treat elderly patients with severe aortic stenosis at high risk for surgery. These patients are also often affected by severe iliac-femoral arteriopathy, rendering the trans-femoral approach unusable. We report our experience with the direct-aortic approach to treat these patients. METHODS: From May 2008 to November 2013 two hundred and thirty-two patients (131 female, 56%) with severe symptomatic aortic stenosis and no reasonable surgical option due to excessive risk were evaluated for TAVI at our department...
February 15, 2015: International Journal of Cardiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"